Drug intelligence / Profile preview

desipramine + naltrexone

Development stage
Phase 3
Modality
Small Molecules
Administration
Oral, Intramuscular
01

Overview

Desipramine + naltrexone is a combination of two small molecule drugs, each with distinct mechanisms of action. Desipramine is a tricyclic antidepressant primarily used for the treatment of depression. It acts mainly as a potent inhibitor of norepinephrine reuptake and, to a lesser extent, serotonin reuptake in the central nervous system. This leads to increased levels of these neurotransmitters in the synaptic cleft and an overall enhancement in serotonergic neurotransmission. Desipramine also has antagonistic effects on histamine-H1 receptors, alpha-1 adrenergic receptors, and muscarinic receptors[1][4]. Naltrexone is an opioid receptor antagonist used primarily for treating alcohol use disorder and opioid use disorder by blocking the rewarding effects of opioids and alcohol at opioid receptors throughout the brain[6]. The combination does not have an established unique indication or brand name; it may be considered experimentally or off-label for research into interactions between antidepressants and opioid systems[2].

02

Targets

ADRA1A (α1A)DOR (Opioid Receptor Delta 1)HRH1 (Histamine H1 Receptor)KOR (Kappa opioid receptor)MOR (Mu opioid receptor)M1 (Muscarinic acetylcholine receptor M1)NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)

Beyond the preview

Go deeper on desipramine + naltrexone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on desipramine + naltrexone.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call